Hermetica Superfood Encyclopedia
The Short Answer
8-Hydroxybriaranes from Junceella fragilis are briarane diterpenoids—most notably fragilide S—that suppress inducible nitric oxide synthase (iNOS) protein expression in LPS-activated macrophages without affecting COX-2. In the sole published in vitro assay, fragilide S reduced iNOS expression to 61.21 ± 9.61% of LPS control at 10 µM in RAW264.7 mouse macrophage cells, representing the only quantified bioactivity data available for this compound class.
CategoryCompound
GroupMarine-Derived
Evidence LevelPreliminary
Primary Keyword8-hydroxybriaranes Junceella fragilis
8-Hydroxybriaranes — botanical close-up
Health Benefits
**iNOS Suppression**
Fragilide S (compound 2) selectively reduces inducible nitric oxide synthase protein levels in LPS-stimulated RAW264.7 macrophages to approximately 61% of inflamed control at 10 µM, suggesting a potential route to limiting nitric oxide-driven inflammation.
**Selective Anti-Inflammatory Action**
Unlike many anti-inflammatory agents, fragilide S does not suppress COX-2 expression (measured at 100.01 ± 5.11% of control), indicating a mechanistically selective profile that could theoretically spare prostaglandin-mediated homeostatic functions.
**Structural Diversity as a Drug Lead Platform**
The fragilide series (R, S, T) and frajunolides (P–S) collectively represent at least eight structurally distinct 8-hydroxybriarane scaffolds from J. fragilis, providing medicinal chemistry starting points for analog development targeting inflammatory enzymes.
**Marine Natural Product Research Value**
As halogenated (fragilide S contains chlorine) and non-halogenated variants exist within the same organism, these compounds offer comparative structure-activity relationship data relevant to designing novel iNOS inhibitors with improved selectivity.
**Macrophage Polarization Modulation (Preclinical)**
By dampening iNOS in activated macrophages without cytotoxic effects at 10 µM in assay conditions, fragilide S may theoretically influence M1-to-M2 macrophage polarization dynamics, though this has not been directly tested.
Origin & History
Natural habitat
8-Hydroxybriaranes are briarane-type diterpenoids isolated from Junceella fragilis, a gorgonian sea whip coral harvested from tropical Indo-Pacific reef ecosystems, with recent specimen collections documented off Hainan Island, China. The coral grows anchored to hard substrates in shallow to mid-depth reef zones and is not cultivated; all research material is obtained via wild collection followed by laboratory solvent extraction and chromatographic purification. No aquaculture or commercial cultivation of J. fragilis for compound production has been reported.
“Junceella fragilis and related gorgonian sea whip corals have no documented history of use in traditional medicine systems, including Traditional Chinese Medicine, Ayurveda, or Pacific Islander ethnomedicine, as isolating specific briarane diterpenoids requires modern analytical chemistry infrastructure unavailable in pre-scientific eras. The broader class of briarane diterpenoids from gorgonian corals has attracted scientific attention since the 1980s as part of systematic marine natural product biodiscovery programs, but J. fragilis-specific compounds—including the fragilide and frajunolide series—appear only in contemporary peer-reviewed isolation studies from the 2010s onward. There are no historical records of coral preparations from this species being used therapeutically, and any medicinal attribution to these compounds is entirely a product of modern pharmacognostic research. The cultural significance of J. fragilis is primarily ecological, as a reef-building organism, rather than medicinal or nutritional.”Traditional Medicine
Scientific Research
The entire published evidence base for 8-hydroxybriaranes from Junceella fragilis consists of small-scale in vitro isolation and bioactivity studies, with the most rigorous published assay using n=2–4 replicates per treatment condition in RAW264.7 macrophage iNOS/COX-2 protein expression assays. Fragilide S is the only compound in this class with a quantified anti-inflammatory endpoint (iNOS reduction to 61.21 ± 9.61% at 10 µM), while fragilides R and T showed no significant activity; frajunolides P–S from the same organism have been structurally characterized but lack published bioactivity data. No animal studies, pharmacokinetic analyses, toxicological evaluations, or human trials have been conducted for any compound in this series. The evidence is entirely preliminary and exploratory, confined to structural elucidation reports and a single cell-based screening study; conclusions about therapeutic relevance in humans cannot be drawn from this dataset.
Preparation & Dosage
Traditional preparation
**Laboratory Isolation (Research Use Only)**
Compounds are extracted from lyophilized or fresh J. fragilis coral tissue using organic solvents (e.g., ethyl acetate, methanol), followed by silica gel column chromatography and HPLC purification; no standardized extraction protocol for commercial use exists.
**In Vitro Test Concentration**
The sole reported bioactive concentration is 10 µM for fragilide S in RAW264.7 cell assays; this is a laboratory molar concentration with no equivalent human dose established.
**No Supplement Forms Available**
8-Hydroxybriaranes are not available as dietary supplements, nutraceuticals, or pharmaceutical preparations; no capsule, tablet, tincture, or standardized extract form has been developed or commercialized.
**No Effective Dose Range Established**
Without bioavailability, pharmacokinetic, or clinical data, no effective dose range, timing, or administration route can be recommended for human use.
**Standardization**
No standardization percentages or quality benchmarks for fragilide content in any extract have been published or regulated.
Nutritional Profile
8-Hydroxybriaranes are secondary metabolites present in trace quantities within the coral matrix; they are not macronutrients, micronutrients, vitamins, or minerals and contribute no caloric, protein, carbohydrate, lipid, or micronutrient value. Their molecular weights range from approximately 454 Da (fragilide R, C24H34O9) to 529 Da (fragilide S, C26H33ClO9), and they are lipophilic diterpenoids likely requiring lipid-soluble delivery vehicles for any potential bioavailability, though no formal bioavailability studies exist. Exact concentrations within coral tissue are unreported in the published literature, and yield from extraction procedures has not been quantified in accessible publications. These compounds are pharmacologically active secondary metabolites, not nutritional constituents, and should be evaluated solely within a pharmaceutical or nutraceutical lead compound framework.
How It Works
Mechanism of Action
Fragilide S (C26H33ClO9), one of three newly characterized 8-hydroxybriaranes from Junceella fragilis, selectively inhibits iNOS protein expression—but not COX-2—in LPS-stimulated RAW264.7 mouse macrophages at 10 µM, reducing iNOS to 61.21 ± 9.61% of LPS-induced control levels. The briarane diterpenoid skeleton, characterized by a 6/10-bicyclic ring system with hydroxyl substitution at C-8 (8α-hydroxy configuration in fragilide S) and additional oxygenated positions, is hypothesized to confer anti-inflammatory bioactivity, though the precise binding target—whether transcriptional (NF-κB pathway suppression) or post-translational—has not been elucidated. Fragilides R and T, differing in oxygenation pattern and methyl group orientation (17β-methyl in fragilide T), showed no measurable effect on iNOS or COX-2 at the same concentration, implying that the 8α-hydroxy and chlorine-bearing structural features of fragilide S are critical pharmacophore elements. No receptor-binding assays, kinetic inhibition studies, or gene expression profiling have been conducted, leaving the upstream molecular target unidentified.
Clinical Evidence
No clinical trials of any design have been conducted for 8-hydroxybriaranes from Junceella fragilis or for any member of the fragilide or frajunolide compound series. The totality of human-relevant evidence is extrapolated solely from one in vitro study using LPS-stimulated mouse macrophages (RAW264.7 cell line), which is a standard but highly simplified inflammatory model with limited translational fidelity. Effect sizes observed in vitro (approximately 39% reduction in iNOS expression for fragilide S at 10 µM) are potentially interesting as a lead compound signal but carry no clinical interpretive weight without pharmacokinetic, in vivo efficacy, and safety data. Confidence in any therapeutic claim for this ingredient class is negligible by clinical standards, and no regulatory body has evaluated these compounds for medicinal use.
Safety & Interactions
No human safety data exist for 8-hydroxybriaranes from Junceella fragilis; no acute toxicity, chronic toxicity, genotoxicity, or carcinogenicity studies have been performed in any species, and no adverse events have been reported because these compounds have never been administered to humans. In the only published in vitro experiment, fragilide S at 10 µM showed no apparent cytotoxicity in RAW264.7 macrophage assay conditions, but cell viability was not the primary endpoint and this does not constitute a safety assessment. No drug interaction data exist; given the compound's potential iNOS-inhibitory activity, theoretical caution regarding additive effects with nitric oxide-modulating drugs (e.g., PDE5 inhibitors, nitrates) could be hypothesized but is entirely speculative. Pregnancy, lactation, pediatric, and geriatric safety profiles are completely unknown; consumption or administration of these compounds outside a controlled research setting is not supported by any evidence and cannot be recommended.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Junceella fragilis diterpenoidsfragilides R, S, Tfrajunolides P-Sbriarane-type diterpenoidssea whip coral metabolites
Frequently Asked Questions
What are 8-hydroxybriaranes and where do they come from?
8-Hydroxybriaranes are a subclass of briarane diterpenoids—bicyclic secondary metabolites with a 6/10-fused ring system and hydroxyl substitution at carbon-8—isolated from Junceella fragilis, a gorgonian sea whip coral found on Indo-Pacific reefs including sites off Hainan Island, China. They include compounds named fragilides R, S, and T, as well as frajunolides P through S, all characterized by nuclear magnetic resonance spectroscopy and high-resolution mass spectrometry. These compounds exist naturally in the coral as chemical defenses and are not found in food, supplements, or traditional medicines.
Does fragilide S actually reduce inflammation?
In one published in vitro study, fragilide S reduced iNOS protein expression to 61.21 ± 9.61% of LPS-stimulated control levels in RAW264.7 mouse macrophage cells at a concentration of 10 µM, representing roughly a 39% reduction in this inflammatory enzyme marker. Importantly, fragilide S did not affect COX-2 expression (100.01 ± 5.11% of control), indicating selectivity for the iNOS pathway. However, these are cell-culture results with no animal or human data to support conclusions about anti-inflammatory efficacy in living organisms.
Are 8-hydroxybriaranes available as supplements?
No—8-hydroxybriaranes from Junceella fragilis are not available in any commercial supplement, nutraceutical, or pharmaceutical product as of current knowledge. These compounds exist only as research-grade isolates obtained through laboratory extraction and chromatographic purification of raw coral material. There is no established manufacturing process, standardized extract, or regulatory-approved form for human consumption.
What is the evidence level for health claims about Junceella fragilis compounds?
The evidence is entirely preliminary, consisting of in vitro cell-based assays with small sample sizes (n=2–4 replicates per condition) and structural chemistry reports; no animal studies, pharmacokinetic data, or human clinical trials exist. Only one compound—fragilide S—has a single quantified bioactivity endpoint, and the broader fragilide and frajunolide series remain pharmacologically uncharacterized. This places the evidence squarely at the exploratory lead-compound discovery stage, far from any basis for health claims.
Is it safe to consume Junceella fragilis coral or its extracts?
There is no evidence that consuming Junceella fragilis coral or crude extracts is safe for humans; no toxicological, pharmacokinetic, or clinical safety studies have been performed on these compounds or on coral-derived preparations from this species. The only available safety-adjacent data is the absence of apparent cytotoxicity in a single in vitro macrophage assay at 10 µM, which is not a substitute for formal safety evaluation. Coral consumption also raises environmental, microbiological, and heavy metal contamination concerns, and no regulatory agency has evaluated J. fragilis materials for human use.
How does fragilide S's mechanism of action differ from typical anti-inflammatory supplements?
Fragilide S selectively suppresses inducible nitric oxide synthase (iNOS) protein levels without inhibiting COX-2, making it mechanistically distinct from NSAIDs and most herbal anti-inflammatory agents. This selective pathway targets nitric oxide-driven inflammation specifically, potentially offering a different therapeutic approach than conventional inflammation-fighting supplements. Research shows it reduces iNOS to approximately 61% of inflamed control levels at 10 µM in macrophage models, suggesting a targeted rather than broad-spectrum anti-inflammatory effect.
What is the current research status on 8-hydroxybriaranes for human inflammatory conditions?
Current evidence for 8-hydroxybriaranes in humans remains limited, with most supporting data derived from in vitro studies using isolated fragilide S on macrophage cell cultures. While laboratory results show promising iNOS suppression, these findings have not yet been extensively validated in human clinical trials or animal models relevant to specific inflammatory diseases. Additional research is needed to establish effective dosing, safety profiles, and therapeutic applications in human subjects before definitive health claims can be made.
Can 8-hydroxybriaranes be combined with other anti-inflammatory supplements or medications?
Due to the limited human research on 8-hydroxybriaranes and their selective iNOS-inhibiting mechanism, specific interaction data with other anti-inflammatory agents, NSAIDs, or prescription medications is not yet well-established. Individuals taking inflammatory medications or considering supplements containing fragilide S should consult healthcare providers to assess potential interactions based on current evidence. The selective COX-2-sparing mechanism suggests theoretical compatibility with certain medications, but clinical confirmation is lacking.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w 8-hydroxybriaranes-junceella-fragilis curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
